No results found. Please try adjusting your search criteria.
The requirements placed on a POI ligand in a PROTAC differ from those of a conventional small molecule drug: potency is less important than reliable, well-characterised binding with a chemically tractable attachment point. This fact has rehabilitated several ligands previously deprioritised due to insufficient activity as standalone inhibitors or agonists, and opened up target classes once considered inaccessible to small molecule approaches.
Kinase targeting ligands
Kinases remain the most extensively explored target class in the PROTAC literature, in part because of the wealth of available, well-characterised kinase inhibitor scaffolds amenable to linker conjugation. BTK ligands based on the ibrutinib scaffold, including ibrutinib (936563-96-1) itself and close analogues with engineered linker exit vectors, are among the most validated in the field; with BTK PROTACs demonstrating degradation in primary patient cells and preclinical models relevant to B-cell malignancies (Buhimschi et al., Biochemistry, 2018). FAK-targeting ligands based on the defactinib (1073154-85-4) scaffold provide entry points into adhesion kinase biology, where degradation rather than inhibition may be needed to fully ablate scaffold-dependent signalling. CDK-targeting ligands, including SNS-032 (345627-80-7) derivatives, are also represented, extending kinase coverage into transcriptional regulation.
KRAS targeting ligands
The emergence of covalent KRAS G12C inhibitors as viable warheads has been one of the most significant recent developments in PROTAC design. KRAS G12C-directed ligand-linker conjugates with linker attachment points, optimised for downstream PROTAC synthesis, lower the barrier to entry for researchers exploring degradation of this historically intractable GTPase. BI-4464 (1227948-02-8) provides complementary coverage as a non-covalent KRAS tool compound.
Epigenetic reader ligands
(+)-JQ1 (1268524-70-4) remains the most widely used BET bromodomain targeting ligand in PROTAC research, having served as the POI-binding component in numerous landmark degraders including early dBET compounds. Its well-defined binding mode in the BRD4 BD1/BD2 acetyl-lysine binding pocket, combined with straightforward synthetic handles, makes it a benchmark for ternary complex optimisation studies (Filippakopoulos et al., Nature, 2010). SMARCA2/BRG1-directed ligands, including SMARCA2 ligand-13 (2660235-29-8) and BRM/BRG1 ligand 1 (1893977-70-2), extend epigenetic coverage into the SWI/SNF chromatin remodelling complex. This target is of rapidly growing interest following demonstration that SMARCA2-selective degradation is synthetically lethal in SMARCA4-mutant cancers (Cantley et al. Nat. Commun., 2022).
Nuclear receptors and other ligands
Androgen receptor antagonist scaffolds, including the phthalazinone-based AR ligand series, provide POI-binding moieties for AR-directed PROTACs relevant to castration-resistant prostate cancer, where degradation of the receptor offers a potential route around resistance to enzalutamide (915087-33-1) and abiraterone (154229-19-3). Tau-targeting ligands are also represented, alongside the FKBP12F36V-directed dTAG targeting ligand (755039-56-6) enabling fusion-tag-dependent chemical genetic degradation systems orthogonal to endogenous target engagement.
Custom PROTAC Synthesis
With POI ligand in hand, the path to a first-generation PROTAC degrader need not be long. Fluorochem’s custom synthesis team can take your chosen warhead, pair it with an appropriate E3 ligase ligand, delivering a bespoke linker-connected chimeric molecule with the turnaround your programme demands. From single exploratory compounds to focused SAR panels, we offer rapid, expert PROTAC assembly built on an extensive in-house building block inventory.